2024年肿瘤健康科技VC市场快照（英）2024

2024 Oncology Healthtech VC Market Snapshot

Introduction

• Global Impact: Cancer remains a leading cause of death globally, accounting for about one-sixth of all deaths. The economic impact of cancer is significant, estimated to cost the global economy over $25 trillion over the coming decades.
• Market Size: The oncology healthtech market is estimated to be around $250 billion, with the cancer screening category being the largest, valued at $100 billion globally and over $40 billion in the U.S. alone.
• Opportunities: Advances in cancer screening technologies, such as liquid biopsies and imaging tests, are expected to drive demand for new cancer detection products. Longer-term, regular multicancer detection is anticipated to become part of routine health screening.

VC Activity

• Total Funding: Since 2020, oncology healthtech companies have raised over $16 billion in venture capital, peaking at $5 billion in 2021.
• Recent Trends:
  • Deal Value: Total deal value reached a low of $2.1 billion in 2023 but has since recovered to $2.8 billion in 2024, with eight deals surpassing $100 million, led by Freenome’s $254 million round.
  • Segments:
    • Diagnostics & Life Sciences: The top segment for oncology VC funding, with $1.4 billion in the trailing 12 months.
    • Treatment & Care: Followed closely with $1.2 billion.
    • Digital Health & Healthcare IT: Generally lesser contributors but attracted more capital in 2021, driven by smaller digital health point solutions.
    • Medical Imaging Analysis: Notable with over $1 billion in VC funding since 2020.

Key Investors

• Top investors include RA Capital Management, Keiretsu Forum, SOSV, Polaris Partners, and Catalio Capital Management, each making over 10 investments in the space.

Exit Activity

• Recent Exits: Few exits in recent years, with notable acquisitions like C2i Genomics by Veracyte for $100.2 million and Carevive Systems by Health Catalyst.
• IPOs: The healthcare IT segment saw a notable IPO with Finland-based Aiforia going public at a valuation near $150 million in December 2021. However, no unicorns have gone public in the past four years.

Top Deals

• Valo: Testing equipment, Series B, $330 million, post-money valuation $1.25 billion.
• Freenome: Cancer screening, Series D, $300 million, Series E, $290 million, post-money valuations $1.4 billion and $2.8 billion respectively.

These key points summarize the main findings and trends in the oncology healthtech VC market as of 2024.